IP Library › Assignment 061165/0501
Patent Assignment
Reel/Frame 061165/0501

Termination and Release of Security Interest in Patents at Reel/Frame: 051057/0848

Recorded: 2022-08-13 Pages: 85
Assignor
BIOPHARMA CREDIT PLC
Executed: 2022-08-12
Assignee
EPIZYME, INC.
400 TECHNOLOGY SQUARE, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties (550)
Inhibitors of Human EZH2, and Methods of Use Thereof
Substituted Purine and 7-Deazapurine Compounds
Carbocycle-Substituted Purine and 7-Deazapurine Compounds
Modulators of Histone Methyltransferase, and Methods of Use Thereof
7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Aryl-Or Heteroaryl-Substituted Benzene Compounds
Substituted Benzene Compounds
Inhibitors of Human EZH2, and Methods of Use Thereof
Salt Form for EZH2 Inhibition
Combination Therapy for Treating Cancer
Inhibitors of Protein Methyltransferase DOT1L and Methods of Use Thereof
Method of Treating Leukemia
Methods of Treating Cancer
Substituted Benzene Compounds
Substituted Benzene Compounds
1,4-Pyridone Compounds
Methods for Treating Cancer
1,4-Pyridone Bicyclic Heteroaryl Compounds
PRMT5 Inhibitors and Uses Thereof
PRMT5 Inhibitors and Uses Thereof
PRMT5 Inhibitors and Uses Thereof
PRMT5 Inhibitors and Uses Thereof
PRMT5 Inhibitors and Uses Thereof
Methods of Inhibiting PRMT5
Substituted 7-Deazapurine Compounds
Injectable Formulations for Treating Cancer
Methods of Synthesizing Substituted Purine Compounds
CARM1 Inhibitors and Uses Thereof
Combination Therapy for Treating Cancer
CARM1 Inhibitors and Uses Thereof
PRMT1 Inhibitors and Uses Thereof
Substituted Benzene Compounds
Arginine Methyltransferase Inhibitors and Uses Thereof
PRMT1 Inhibitors and Uses Thereof
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
PRMT1 Inhibitors and Uses Thereof
Arginine Methyltransferase Inhibitors and Uses Thereof
Arginine Methyltransferase Inhibitors and Uses Thereof
Arginine Methyl Transferase Inhibtors and Uses Thereof
Arginine Methyltransferase Inhibitors and Uses Thereof
Arginine Methyltransferase Inhibitors and Uses Thereof
Substituted Purine Compounds
Substituted Benzene Compounds
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Hydrochloride Salt Form for EZH2 Inhibition
Method of Treating Cancer
Methods for Treating Cancer
Combination Therapy for Treating Cancer
Methods for Treating Cancer
EZH2 Inhibitors for Treating Lymphoma
Substituted Benzene and 6,5-Fused Bicyclic Heteroaryl Compounds
PRMT5 Inhibitors and Uses Thereof
PRMT5 Inhibitors and Uses Thereof
DOT1L Inhibition in Patients with MN1-High Aml
PRMT5 Inhibitors and Uses Thereof
DOT1L Inhibitors and Uses Thereof
Combination Therapy for Treating Cancer
Combination Therapy for Treating Cancer
Isoxazole Carboxamide Compounds
Substituted Cyclohexylamine Compounds
Substituted Pyrrolidine Compounds
Smyd Inhibitors
Substituted Pyrrolidine Carboxamide Compounds
Isoxazole Carboxamides as Irreversible Smyd Inhibitors
Substituted Piperidine Compounds
Arginine Methyltransferase Inhibitors and Uses Thereof
Salts, Co-Crystals, Amorphous Forms, and Crystalline Forms of a Co-Activator-Associated Arginine Methyltransferase 1 (CARM1) Inhibitor
Salts, Co-Crystals, Amorphous Forms, and Crystalline Forms of an Arginine Methyltransferase Inhibitor
Arginine Methyltransferase Inhibitors and Uses Thereof
CARM1 Inhibitors and Uses Thereof
Arginine Methyltransferase Inhibitors and Uses Thereof
CARM1 Inhibitors and Uses Thereof
Injectable Formulations for Treating Cancer
CARM1 Inhibitors and Uses Thereof
Heterocycle Substituted Amino-Pyridine Compounds and Methods of Use Thereof
Method for Treating Cancer
Method for Treating Cancer
Methods for Treating Cancer
Combination Therapy for Treating Cancer
Combination Therapy for Treating Cancer
EZH2 Inhibitors for Treating Lymphoma
Method for Treating Cancer
Method of Treating Malignant Rhabdoid Tumor of the Ovary (Mrto)/Small Cell Cancer of the Ovary of the Hypercalcemic Type (Sccoht) with an EZH2 Inhibitor
Method of Treating Medulloblastoma with an EZH2 Inhibitor
Flow Cytometric Assay for Monitoring Epigenetic Status
Pediatric Dosing for Treatment of Cancer with an EZH2 Inhibitor
Inhibitors of EZH2 and Methods of Use Thereof
Combination Therapy for Treating Cancer
Arginine Methyltransferase Inhibitors and Uses Thereof
Methods of Treating Cancer
Amine-Substituted Aryl or Heteroaryl Compounds
Use of EZH2 Inhibitors for Treating Cancer
EZH2 Inhibitors for Treating Cancer
Crebbp Related Cancer Therapy
Substituted Fused Bi- or Tri- Heterocyclic Compounds as EHMT2 Inhibitors
Kat Inhibitors
Combination Therapy for Treating Cancer
Amine-Substituted Heterocyclic Compounds as Ehmtz Inhibitors and Methods of Use Thereof
Cancer Treatment Modalities
Inhibition of SMARCA2 for Treatment of Cancer
Combination Therapy for Treating Cancer
Methods of Using EHMT2 Inhibitors
Combination Therapies with EHMT2 Inhibitors
Use of EZH2 Inhibitors for Treating Cancer
Inhibitors of EZH2 and Methods of Use Thereof
Methods of Treating Cancer by Inhibiting SETD2
Combination Therapy for Treating Cancer
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Derivatives Thereof
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors, Salts Thereof, and Methods of Synthesis Thereof
Methods of Using EHMT2 Inhibitors in Immunotherapies
Methods of Using EHMT2 Inhibitors in Preventing or Treating Blood Disorders
Myst Family Histone Acetyltransferase Inhibitors
Pyridin-2-One Compounds and Methods of Using Same
Substituted Indoles and Methods of Use Thereof
Inhibitors of Human EZH2 and Methods of Use Thereof
Patent: 8,895,245 →
Application: 13/230,703 →
Publication: US 2012/0071418
Substituted Purine and 7-Deazapurine Compounds
Patent: 8,580,762 →
Application: 13/310,157 →
Publication: US 2012/0142625
Inhibitors of Human EZH2, and Methods of Use Thereof
Patent: 9,175,331 →
Application: 13/418,242 →
Publication: US 2013/0040906
Aryl- or Heteroaryl-Substituted Benzene Compounds
Patent: 8,410,088 →
Application: 13/447,007 →
Publication: US 2012/0264734
Aryl- or Heteroaryl-Substituted Benzene Compounds
Patent: 8,765,732 →
Application: 13/722,807 →
Publication: US 2013/0123234
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 8,598,167 →
Application: 13/938,067 →
Publication: US 2013/0317026
Inhibitors of Human EZH2 and Methods of Use Thereof
Patent: 8,691,507 →
Application: 13/949,026 →
Publication: US 2013/0303555
Carbocycle-Substituted Purine And 7-Deazapurine Compounds
Patent: 9,394,310 →
Application: 13/991,145 →
Publication: US 2013/0338173
Modulators of Histone Methyltransferase, and Methods of Use Thereof
Patent: 9,029,343 →
Application: 13/991,321 →
Publication: US 2013/0310333
7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof
Patent: 9,145,438 →
Application: 13/991,328 →
Publication: US 2013/0310334
7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof
Patent: 8,722,877 →
Application: 14/018,171 →
Publication: US 2014/0073597
Methods of Treating Cancer
Patent: 9,688,665 →
Application: 14/054,646 →
Publication: US 2014/0128393
Substituted Benzene Compounds
Patent: 9,006,242 →
Application: 14/054,695 →
Publication: US 2014/0107122
Substituted Purine and 7-Deazapurine Compounds
Patent: 9,096,634 →
Application: 14/055,510 →
Publication: US 2014/0051654
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 8,962,620 →
Application: 14/070,675 →
Publication: US 2014/0057891
Dihydropyridin-2-One Benzamine Compounds
Patent: 9,376,422 →
Application: 14/110,873 →
Publication: US 2014/0142083
PRMT5 Inhibitors and Uses Thereof
Patent: 8,906,900 →
Application: 14/136,551 →
Publication: US 2014/0228343
PRMT5 Inhibitors and Uses Thereof
Patent: 9,365,555 →
Application: 14/136,559 →
Publication: US 2014/0213582
PRMT5 Inhibitors and Uses Thereof
Patent: 8,993,555 →
Application: 14/136,569 →
Publication: US 2014/0329794
PRMT5 Inhibitors and Uses Thereof
Patent: 9,221,794 →
Application: 14/136,691 →
Publication: US 2014/0228360
PRMT5 Inhibitors and Uses Thereof
Patent: 8,940,726 →
Application: 14/136,738 →
Publication: US 2014/0221345
Combination Therapy for Treating Cancer
Patent: 9,446,064 →
Application: 14/210,511 →
Publication: US 2014/0323421
Substituted Benzene Compounds
Patent: 9,243,001 →
Application: 14/210,638 →
Publication: US 2014/0315945
CARM1 Inhibitors and Uses Thereof
Patent: 9,346,802 →
Application: 14/210,672 →
Publication: US 2014/0288067
Methods of Synthesizing Substituted Purine Compounds
Patent: 9,175,032 →
Application: 14/210,888 →
Publication: US 2015/0011495
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 9,045,477 →
Application: 14/211,248 →
Publication: US 2014/0296283
PRMT1 Inhibitors and Uses Thereof
Patent: 8,952,026 →
Application: 14/212,057 →
Publication: US 2014/0288140
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,346,761 →
Application: 14/212,102 →
Publication: US 2014/0323537
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,045,455 →
Application: 14/212,142 →
Publication: US 2014/0288128
PRMT1 Inhibitors and Uses Thereof
Patent: 9,023,883 →
Application: 14/212,354 →
Publication: US 2014/0288141
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,120,757 →
Application: 14/212,543 →
Publication: US 2014/0315904
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,133,189 →
Application: 14/212,713 →
Publication: US 2014/0288105
PRMT1 Inhibitors and Uses Thereof
Patent: 9,447,079 →
Application: 14/212,965 →
Publication: US 2014/0288129
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,394,258 →
Application: 14/213,144 →
Publication: US 2014/0288124
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,365,527 →
Application: 14/213,272 →
Publication: US 2014/0315961
Aryl- or Heteroaryl-Substituted Benzene Compounds
Patent: 9,090,562 →
Application: 14/275,667 →
Publication: US 2014/0288041
Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
Application: 14/282,837 →
Publication: US 2014/0342920
Inhibitors of Human EZH2, and Methods of Use Thereof
Patent: 9,334,527 →
Application: 14/290,642 →
Publication: US 2014/0275081
Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
Patent: 9,394,283 →
Application: 14/394,431 →
Publication: US 2015/0065503
Combination Therapy for Treating Cancer
Application: 14/394,463 →
Publication: US 2015/0051163
Inhibitors of Protein Methyltransferase DOT1L and Methods of Use Thereof
Application: 14/420,877 →
Publication: US 2015/0284422
Method of Treating Leukemia
Patent: 9,597,348 →
Application: 14/426,331 →
Publication: US 2015/0216890
Substituted Benzene Compounds
Application: 14/435,704 →
Publication: US 2015/0284370
PRMT5 Inhibitors and Uses Thereof
Patent: 9,388,173 →
Application: 14/515,154 →
Publication: US 2015/0133427
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 9,637,472 →
Application: 14/536,162 →
Publication: US 2015/0065483
Wind Turbine Power Enhancement, Utilizing Convergent Nozzle and Embedded Blades
Application: 14/540,997 →
Publication: US 2015/0139778
PRMT5 Inhibitors and Uses Thereof
Patent: 9,266,836 →
Application: 14/561,538 →
Publication: US 2015/0191432
PRMT5 Inhibitors and Uses Thereof
Patent: 9,365,519 →
Application: 14/619,371 →
Publication: US 2015/0252031
Substituted Benzene Compounds
Patent: 9,089,575 →
Application: 14/639,878 →
Publication: US 2015/0174136
1,4-Pyridone Compounds
Application: 14/654,113 →
Publication: US 2015/0344427
DOT1L Inhibitors for Use in the Treatment of Leukemia
Application: 14/654,125 →
Publication: US 2015/0342979
1,4-Pyridone Bicyclic Heteroaryl Compounds
Patent: 9,701,666 →
Application: 14/654,131 →
Publication: US 2015/0344459
PRMT5 Inhibitors and Uses Thereof
Application: 14/654,161 →
Publication: US 2015/0361042
Methods of Inhibiting PRMT5
Application: 14/654,213 →
Publication: US 2015/0344457
PRMT5 Inhibitors Containing a Dihydro- or Tetrahydroisoquinoline and Uses Thereof
Patent: 9,745,291 →
Application: 14/654,226 →
Publication: US 2015/0344433
Tetrahydro- and Dihydro-Isoquinoline PRMT5 Inhibitors and Uses Thereof
Patent: 9,604,930 →
Application: 14/654,253 →
Publication: US 2015/0344434
PRMT5 Inhibitors and Uses Thereof
Patent: 9,611,257 →
Application: 14/654,276 →
Publication: US 2015/0344463
PRMT5 Inhibitors and Uses Thereof
Patent: 9,908,887 →
Application: 14/654,303 →
Publication: US 2016/0214985
PRMT1 Inhibitors and Uses Thereof
Patent: 9,475,776 →
Application: 14/675,781 →
Publication: US 2015/0284334
Modulators of Histone Methyltransferase, and Methods of Use Thereof
Application: 14/680,339 →
Publication: US 2016/0068559
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,440,950 →
Application: 14/697,420 →
Publication: US 2016/0108018
Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds
Patent: 9,365,570 →
Application: 14/699,100 →
Publication: US 2015/0246916
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 9,206,157 →
Application: 14/733,690 →
Publication: US 2015/0266854
Substituted Benzene Compounds
Patent: 9,532,992 →
Application: 14/742,466 →
Publication: US 2015/0352119
Aryl- or Heteroaryl-Substituted Benzene Compounds
Patent: 9,549,931 →
Application: 14/742,481 →
Publication: US 2015/0353494
Substituted Purine and 7-Deazapurine Compounds
Application: 14/752,023 →
Publication: US 2015/0366893
Substituted Benzene Compounds
Application: 14/774,935 →
Publication: US 2016/0031907
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 9,776,996 →
Application: 14/774,937 →
Publication: US 2016/0024081
Pyrazole Derivatives as PRMT1 Inhibitors and Uses Thereof
Application: 14/775,175 →
Publication: US 2016/0039767
1-Phenoxy-3-(Alkylamino)-Propan-2-Ol Derivatives as CARM1 Inhibitors and Uses Thereof
Patent: 9,718,816 →
Application: 14/775,197 →
Publication: US 2016/0052922
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 14/775,213 →
Publication: US 2016/0031839
Pyrazole Derivatives as Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,776,972 →
Application: 14/775,232 →
Publication: US 2016/0137609
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,765,035 →
Application: 14/775,246 →
Publication: US 2016/0024017
CARM1 Inhibitors and Uses Thereof
Patent: 9,738,651 →
Application: 14/775,766 →
Publication: US 2016/0039834
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,598,374 →
Application: 14/775,794 →
Publication: US 2016/0024016
Combination Therapy for Treating Cancer
Application: 14/776,669 →
Publication: US 2016/0045531
Injectable Formulations for Treating Cancer
Application: 14/777,284 →
Publication: US 2016/0022725
Methods of Synthesizing Substituted Purine Compounds
Patent: 9,738,679 →
Application: 14/777,317 →
Publication: US 2016/0024134
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,630,961 →
Application: 14/808,270 →
Publication: US 2016/0185772
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,724,332 →
Application: 14/808,290 →
Publication: US 2016/0184267
7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof
Application: 14/867,356 →
Publication: US 2016/0251390
Aryl- or Heteroaryl-Substituted Benzene Compounds
Patent: 9,522,152 →
Application: 14/876,658 →
Publication: US 2016/0022693
PRMT5 Inhibitors and Uses Thereof
Patent: 9,732,072 →
Application: 14/882,638 →
Publication: US 2016/0137631
Substituted Purine Compounds
Patent: 9,688,714 →
Application: 14/902,150 →
Publication: US 2016/0368943
Substituted Benzene Compounds
Application: 14/904,801 →
Publication: US 2016/0194316
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Patent: 9,624,205 →
Application: 14/904,803 →
Publication: US 2016/0152604
Methods of Synthesizing Substituted Purine Compounds
Patent: 9,701,707 →
Application: 14/929,736 →
Publication: US 2016/0289260
PRMT5 Inhibitors and Uses Thereof
Patent: 9,765,068 →
Application: 14/995,092 →
Publication: US 2016/0368907
Substituted Benzene Compounds
Application: 15/004,224 →
Publication: US 2016/0244464
Hydrochloride Salt Form for EZH2 Inhibition
Application: 15/029,848 →
Publication: US 2016/0237068
Method of Treating Cancer
Application: 15/029,914 →
Publication: US 2016/0228447
Methods for Treating Cancer
Application: 15/036,544 →
Publication: US 2016/0296548
PRMT5 Inhibitors and Uses Thereof
Patent: 9,675,614 →
Application: 15/054,193 →
Publication: US 2017/0027935
CARM1 Inhibitors and Uses Thereof
Application: 15/092,903 →
Publication: US 2017/0056409
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,732,041 →
Application: 15/093,103 →
Publication: US 2017/0057926
Combination Therapy for Treating Cancer
Application: 15/101,577 →
Publication: US 2016/0303135
Inhibitors of Human EZH2, and Methods of Use Thereof
Application: 15/132,610 →
Publication: US 2017/0065600
Inhibitors of Human EZH2, and Methods of Use Thereof
Patent: 9,949,999 →
Application: 15/132,724 →
Publication: US 2017/0065628
PRMT5 Inhibitors and Uses Thereof
Application: 15/150,759 →
Publication: US 2017/0088541
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/150,772 →
Publication: US 2017/0088529
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 15/162,384 →
Publication: US 2016/0326170
Substituted Benzene Compounds
Application: 15/162,453 →
Publication: US 2016/0332969
Inhibitors of Protein Methyltransferase DOT1L and Methods of Use Thereof
Application: 15/176,052 →
Publication: US 2017/0137455
PRMT5 Inhibitors and Uses Thereof
Patent: 9,777,008 →
Application: 15/177,056 →
Publication: US 2017/0114061
Arginine Methyltransferase Inhibitors and Uses Thereof
Patent: 9,943,504 →
Application: 15/178,696 →
Publication: US 2017/0119735
Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
Patent: 9,872,862 →
Application: 15/199,522 →
Publication: US 2017/0143729
Method for Treating Cancer
Patent: 9,889,138 →
Application: 15/211,792 →
Publication: US 2016/0346293
PRMT1 Inhibitors and Uses Thereof
Application: 15/231,651 →
Publication: US 2017/0182005
Combination Therapy for Treating Cancer
Application: 15/248,080 →
Publication: US 2017/0080010
PRMT1 Inhibitors and Uses Thereof
Patent: 9,868,703 →
Application: 15/276,324 →
Publication: US 2017/0233347
EZH2 Inhibitors for Treating Lymphoma
Application: 15/319,535 →
Publication: US 2017/0216300
Substituted Benzene and 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 15/321,256 →
Publication: US 2017/0217941
PRMT5 Inhibitors and Uses Thereof
Application: 15/321,270 →
Publication: US 2017/0210751
PRMT5 Inhibitors and Uses Thereof
Application: 15/321,280 →
Publication: US 2017/0198006
DOT1L Inhibition in Patients with MN1-High Aml
Application: 15/327,341 →
Publication: US 2017/0166976
Aryl- or Heteroaryl-Substituted Benzene Compounds
Application: 15/346,677 →
Publication: US 2017/0119780
Substituted Benzene Compounds
Application: 15/359,538 →
Publication: US 2017/0290837
Biomarkers for Response to EZH2 Inhibitors
Application: 15/380,807 →
Publication: US 2017/0138946
Method of Treating Leukemia
Application: 15/387,240 →
Publication: US 2017/0165288
Tetrahydro- and Dihydro-Isoquinoline PRMT5 Inhibitors and Uses Thereof
Application: 15/419,260 →
Publication: US 2017/0334861
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/421,699 →
Publication: US 2017/0267642
PRMT5 Inhibitors and Uses Thereof
Application: 15/438,408 →
Publication: US 2017/0240537
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 15/487,737 →
Publication: US 2018/0065954
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 15/492,506 →
Publication: US 2018/0072702
Method of Treating Cancer
Application: 15/496,653 →
Publication: US 2018/0071300
PRMT5 Inhibitors and Uses Thereof
Application: 15/501,550 →
Publication: US 2017/0224685
DOT1L Inhibitors and Uses Thereof
Application: 15/502,623 →
Publication: US 2017/0335402
Combination Therapy for Treating Cancer
Application: 15/503,542 →
Publication: US 2017/0232030
Substituted Pyrrolidine Carboxamide Compounds
Application: 15/510,583 →
Publication: US 2017/0247326
Substituted 1,2,3-Triazoles as Smyd Inhibitors for Treating Cancer
Application: 15/510,586 →
Publication: US 2017/0355695
Substituted Piperidine Compounds
Application: 15/510,588 →
Publication: US 2017/0362217
Isoxazole Carboxamides as Irreversible SMYD Inhibitors
Application: 15/510,589 →
Publication: US 2018/0230110
Isoxazole Carboxamide Compounds
Application: 15/510,593 →
Publication: US 2017/0190676
Substituted Pyrrolidine Compounds
Application: 15/510,602 →
Publication: US 2017/0253601
Substituted Isoxazoles for Treating Cancer
Application: 15/510,605 →
Publication: US 2017/0362191
CARM1 Inhibitors and Uses Thereof
Application: 15/511,503 →
Publication: US 2017/0305922
CARM1 Inhibitors and Uses Thereof
Application: 15/511,505 →
CARM1 Inhibitors and Uses Thereof
Application: 15/511,507 →
Publication: US 2017/0283440
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/511,509 →
Publication: US 2017/0291905
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/511,514 →
Publication: US 2017/0280720
Salts, Co-Crystals, Amorphous Forms, and Crystalline Forms of a Co-Activator-Associated Arginine Methyltransferase 1 (CARM1) Inhibitor
Application: 15/511,520 →
Publication: US 2017/0298073
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/511,523 →
Publication: US 2017/0283400
Heterocycle Substituted Amino-Pyridine Compounds and Methods of Use Thereof
Application: 15/511,779 →
Publication: US 2017/0291890
Combination Therapy for Treating Cancer
Application: 15/512,527 →
Publication: US 2019/0083521
Injectable Formulations for Treating Cancer
Application: 15/512,528 →
Publication: US 2017/0290765
Method for Treating Cancer
Application: 15/527,375 →
Publication: US 2017/0360797
Treatment of Leukemia via the Administration of DOT1L Inhibitor Pinometostat
Application: 15/533,205 →
Publication: US 2019/0076455
Combination Therapy for Treating Cancer
Application: 15/547,427 →
Publication: US 2018/0028552
Combination Therapy for Treating Cancer
Application: 15/567,838 →
Publication: US 2018/0289717
EZH2 Inhibitors for Treating Lymphoma
Application: 15/580,908 →
Publication: US 2018/0311251
PRMT5 Inhibitors and Uses Thereof
Application: 15/586,775 →
Publication: US 2018/0098987
Aryl-Or Heteroaryl-Substituted Benzene Compounds
Patent: 9,855,275 →
Application: 15/598,078 →
Publication: US 2017/0252349
Methods of Treating Cancer
Application: 15/598,261 →
Publication: US 2017/0305889
Methods of Treating Cancer
Application: 15/598,262 →
Publication: US 2017/0305890
Amine-Substituted Aryl or Heteroaryl Compounds
Application: 15/601,888 →
Publication: US 2017/0355712
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/622,213 →
1,4-Pyridone Bicyclic Heteroaryl Compounds
Application: 15/625,779 →
Publication: US 2018/0134692
Substituted Purine Compounds
Application: 15/632,173 →
Publication: US 2018/0127451
Methods of Synthesizing Substituted Purine Compounds
Application: 15/635,030 →
Publication: US 2018/0134744
Methods of Synthesizing Substituted Purine Compounds
Application: 15/635,032 →
Publication: US 2018/0134745
CARM1 Inhibitors and Uses Thereof
Patent: 9,856,267 →
Application: 15/648,701 →
Publication: US 2017/0320883
PRMT5 Inhibitors Containing a Dihydro- or Tetrahydroisoquinoline and Uses Thereof
Application: 15/652,788 →
Publication: US 2018/0162847
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/675,341 →
Publication: US 2018/0105497
Pyrazole Derivatives as Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/677,238 →
Publication: US 2018/0237397
PRMT5 Inhibitors and Uses Thereof
Application: 15/679,655 →
Publication: US 2018/0186798
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 15/693,680 →
Publication: US 2018/0208591
PRMT5 Inhibitors and Uses Thereof
Application: 15/707,678 →
Publication: US 2019/0083482
Method for Treating Cancer
Application: 15/754,684 →
Publication: US 2018/0235975
Method of Treating Malignant Rhabdoid Tumor of the Ovary (Mrto)/Small Cell Cancer of the Ovary of the Hypercalcemic Type(Sccoht) with an EZH2 Inhibitor
Application: 15/762,839 →
Publication: US 2018/0296563
Method of Treating Medulloblastoma with an EZH2 Inhibitor
Application: 15/766,474 →
Publication: US 2019/0083504
Flow Cytometry for Monitoring Histone H3 Methylation Status
Application: 15/773,420 →
Publication: US 2018/0321256
Pediatric Dosing for Treatment of Cancer with an EZH2 Inhibitor
Application: 15/773,757 →
Publication: US 2019/0070188
Inhibitors of Human EZH2, and Methods of Use Thereof
Application: 15/800,983 →
Publication: US 2018/0243315
Substituted Purine and 7-Deazapurine Compounds
Application: 15/802,979 →
Publication: US 2018/0280422
Combination Therapy for Treating Cancer
Application: 15/809,445 →
Publication: US 2018/0280402
Aryl-Or Heteroaryl-Substituted Benzene Compounds
Application: 15/816,907 →
Publication: US 2018/0318309
CARM1 Inhibitors and Uses Thereof
Application: 15/835,758 →
Publication: US 2018/0282343
Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
Application: 15/837,390 →
Publication: US 2018/0243316
PRMT5 Inhibitors and Uses Thereof
Application: 15/844,097 →
Publication: US 2018/0303822
PRMT1 Inhibitors and Uses Thereof
Application: 15/850,367 →
Publication: US 2018/0265478
Method for Treating Cancer
Application: 15/851,978 →
Publication: US 2018/0133224
PRMT5 Inhibitors and Uses Thereof
Application: 15/866,045 →
Publication: US 2018/0298010
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/881,323 →
Publication: US 2018/0289671
Inhibitors of Human EZH2, and Methods of Use Thereof
Application: 15/924,663 →
Publication: US 2018/0271892
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 15/928,550 →
Publication: US 2018/0290982
Methods of Treating Cancer
Application: 15/979,916 →
Publication: US 2019/0100514
Methods of Treating Cancer
Application: 15/987,000 →
Hydrochloride Salt Form for EZH2 Inhibition
Application: 16/000,539 →
Publication: US 2018/0282312
PRMT1 Inhibitors and Uses Thereof
Application: 16/042,542 →
Publication: US 2019/0022064
Inhibitors of EZH2 and Methods of Use Thereof
Application: 16/060,164 →
Publication: US 2021/0052595
Combination Therapy for Treating Cancer
Application: 16/073,558 →
Publication: US 2019/0151325
Methods of Treating Cancer
Application: 16/075,855 →
Publication: US 2019/0038633
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 16/101,176 →
Publication: US 2019/0077795
Substituted Benzene Compounds
Application: 16/120,702 →
Publication: US 2019/0060322
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 16/124,936 →
Publication: US 2019/0100496
Inhibitors of Protein Methyltransferase DOT1L and Methods of Use Thereof
Application: 16/134,520 →
Publication: US 2019/0100552
Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
Application: 16/148,576 →
Publication: US 2019/0153540
CARM1 Inhibitors and Uses Thereof
Application: 16/149,519 →
Publication: US 2019/0135819
Substituted Cyclohexylamine Compounds
Application: 16/165,480 →
Publication: US 2020/0123142
EZH2 Inhibitors for Treating Lymphoma
Application: 16/181,747 →
Publication: US 2019/0175604
Method of Treating Leukemia
Application: 16/214,783 →
Publication: US 2019/0216838
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 16/217,881 →
Publication: US 2019/0218194
Method of Treating Cancer
Application: 16/237,867 →
Publication: US 2019/0240230
Isoxazole Carboxamides as Irreversible SMYD Inhibitors
Application: 16/245,986 →
Publication: US 2019/0241529
Combination Therapy for Treating Cancer
Application: 16/248,925 →
Publication: US 2020/0030355
EZH2 Inhibitors for Treating Lymphoma
Application: 16/250,211 →
Publication: US 2019/0255060
Smyd Inhibitors
Application: 16/269,338 →
Publication: US 2019/0322660
Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
Application: 16/270,752 →
Publication: US 2019/0269692
Aryl-Or Heteroaryl-Substituted Benzene Compounds
Application: 16/291,800 →
Publication: US 2019/0192526
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 16/299,722 →
Publication: US 2019/0300502
Use of EZH2 Inhibitors for Treating Cancer
Application: 16/306,182 →
Publication: US 2022/0288085
EZH2 Inhibitors for Treating Cancer
Application: 16/310,597 →
Publication: US 2019/0328743
Crebbp Related Cancer Therapy
Application: 16/320,447 →
Publication: US 2019/0270797
Substituted Fused Bi- or Tri- Heterocyclic Compounds as EHMT2 Inhibitors
Application: 16/338,093 →
Publication: US 2020/0039961
Methods of Synthesizing Substituted Purine Compounds
Application: 16/356,198 →
Publication: US 2019/0300561
Methods of Synthesizing Substituted Purine Compounds
Application: 16/356,384 →
Publication: US 2019/0300562
Combination Therapy for Treating Cancer
Application: 16/372,657 →
Publication: US 2019/0315725
Tetrahydro- and Dihydro-Isoquinoline PRMT5 Inhibitors and Uses Thereof
Application: 16/395,844 →
Publication: US 2019/0343826
Injectable Formulations for Treating Cancer
Application: 16/396,017 →
Publication: US 2019/0350959
DOT1L Inhibition in Patients with MN1-High Aml
Application: 16/402,891 →
Publication: US 2019/0276899
Treatment of Leukemia via the Administration of DOT1L Inhibitor Pinometostat
Application: 16/415,325 →
Publication: US 2020/0009176
Substituted Pyrrolidine Carboxamide Compounds
Application: 16/423,618 →
Publication: US 2020/0048195
Injectable Formulations for Treating Cancer
Application: 16/433,259 →
Publication: US 2019/0388335
DOT1L Inhibitors and Uses Thereof
Application: 16/441,381 →
Publication: US 2020/0080155
Method for Treating Cancer
Application: 16/444,579 →
Publication: US 2020/0009152
Inhibitors of Human EZH2, and Methods of Use Thereof
Application: 16/453,501 →
Publication: US 2020/0016162
EZH2 Inhibitors for Treating Lymphoma
Application: 16/454,835 →
Publication: US 2020/0022987
Compounds Containing a Sulfonic Group as Kat Inhibitors
Application: 16/464,584 →
Publication: US 2022/0267260
Combination Therapy for Treating Cancer
Application: 16/465,736 →
Publication: US 2020/0078362
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Methods of Use Thereof
Application: 16/471,151 →
Publication: US 2020/0039998
Cancer Treatment Modalities
Application: 16/482,748 →
Publication: US 2019/0350929
Inhibition of SMARCA2 for Treatment of Cancer
Application: 16/489,489 →
Publication: US 2020/0069669
Combination Therapy for Treating Cancer
Application: 16/499,476 →
Publication: US 2021/0100810
Methods of Using EHMT2 Inhibitors
Application: 16/499,480 →
Publication: US 2020/0113901
PRMT5 Inhibitors and Uses Thereof
Application: 16/504,910 →
Publication: US 2020/0022973
Substituted Pyrrolidine Compounds
Application: 16/531,798 →
Publication: US 2020/0102314
Combination Therapy for Treating Cancer
Application: 16/562,683 →
Publication: US 2020/0101081
Combination Therapy for Treating Cancer
Application: 16/573,371 →
Publication: US 2020/0113911
DOT1L Inhibitors for Use in the Treatment of Leukemia
Application: 16/575,957 →
Publication: US 2020/0113923
Isoxazole Carboxamide Compounds
Application: 16/588,209 →
Publication: US 2020/0148650
Method of Treating Malignant Rhabdoid Tumor of the Ovary (Mrto)/Small Cell Cancer of the Ovary of the Hypercalcemic Type(Sccoht) with an EZH2 Inhibitor
Application: 16/593,010 →
Publication: US 2020/0138825
Combination Therapies with EHMT2 Inhibitors
Application: 16/606,833 →
Publication: US 2020/0054635
Method for Treating Cancer
Application: 16/660,185 →
Publication: US 2020/0155561
Processing Method of Substrate to Be Processed and Computer Readable Storage Medium
Application: 61/252,188 →
Inhibitors of Human EZH2, and Methods of Use Thereof
Application: 61/381,684 →
7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof
Application: 61/419,504 →
Modulators of Histone Methyltransferase, and Methods of Use Thereof
Application: 61/419,591 →
Substituted Purine And 7-Deazapurine Compounds
Application: 61/419,661 →
Carbocycle-Substituted Purine and 7-Deazapurine Compounds
Application: 61/419,668 →
Aryl-Or Heteroaryl-Substituted Pyrazolopyridine Compounds
Application: 61/447,625 →
Substituted Pyrazolopyridine Compounds
Application: 61/447,626 →
Aryl-Or Heteroaryl-Substituted Indazole Compounds
Application: 61/447,627 →
Susbstituted Indazole Compounds
Application: 61/447,629 →
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 61/447,632 →
Aryl-or Heteroaryl-Substituted Benzene Compounds
Application: 61/474,821 →
Substituted Benzene Compounds
Application: 61/474,825 →
Aryl- or Heteroaryl-Substituted Benzene Compounds
Application: 61/499,595 →
Substituted Benzene Compounds
Application: 61/505,676 →
Combination Therapy for Treating Cancer
Application: 61/624,194 →
Salt Form For EZH2 Inhibition
Application: 61/624,215 →
Inhibitors of Protein Methyltransferase DOT1L and Methods of Use Thereof
Application: 61/682,090 →
Method of Treating Leukemia
Application: 61/697,721 →
Methods of Treating Cancer
Application: 61/714,045 →
Substitute Benzene Compounds
Application: 61/714,140 →
Substituted Benzene Compounds
Application: 61/714,145 →
1,4-Pyridone Compounds
Application: 61/745,182 →
1,4-Pyridone Bicyclic Heteroaryl Compounds
Application: 61/745,194 →
Methods for Treating Cancer
Application: 61/745,294 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/745,393 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/745,477 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/745,485 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/745,490 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/745,494 →
Methods of Inhibiting PRMT5
Application: 61/745,537 →
Methods of Treating Cancer
Application: 61/758,972 →
Substituted Benzene Compounds
Application: 61/780,703 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/781,046 →
PRMT1 Inhibitors and Uses Thereof
Application: 61/781,048 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/781,051 →
PRMT1 Inhibitors and Uses Thereof
Application: 61/781,052 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/781,054 →
PRMT1 Inhibitors and Uses Thereof
Application: 61/781,055 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/781,056 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/781,059 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/781,063 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/784,958 →
Substituted 7-Deazapurine Compounds
Application: 61/784,987 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/785,025 →
1,4-Pyridone Bicyclic Heteroaryl Compounds
Application: 61/785,042 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/785,095 →
Combination Therapy for Treating Cancer
Application: 61/785,169 →
Treatment Methods Using Adenovirus
Application: 61/785,287 →
Combination Therapy For Treating Cancer
Application: 61/785,446 →
Substituted Benzene Compounds
Application: 61/786,277 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/790,525 →
PRMT5 Inhibitors and Uses Thereof
Application: 61/790,928 →
Substituted Benzene Compounds
Application: 61/791,858 →
CARM1 Inhibitors and Uses Thereof
Application: 61/794,442 →
Injectable Formulations for Treating Cancer
Application: 61/794,892 →
CARM1 Inhibitors and Uses Thereof
Application: 61/798,109 →
Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds
Application: 61/798,113 →
Methods of Synthesizing Substituted Purine Compounds
Application: 61/799,147 →
Substituted Purine Compounds
Application: 61/842,701 →
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 61/856,507 →
Substituted Benzene Compounds
Application: 61/856,512 →
Substituted Benzene Compounds
Application: 61/856,545 →
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 61/856,625 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 61/876,034 →
Hydrochloride Salt Form For EZH2 Inhibition
Application: 61/891,786 →
Method for Treating Cancer
Application: 61/893,031 →
Combination Therapy For Treating Cancer
Application: 61/900,939 →
Methods For Treating Cancer
Application: 61/903,912 →
Combination Therapy For Treating Cancer
Application: 61/912,872 →
Method of Treating Cancer
Application: 61/912,938 →
Combination Therapy for Treating Cancer
Application: 61/913,063 →
Combination Therapy for Treating Cancer
Application: 61/934,388 →
CARM1 Inhibitors and Uses Thereof
Application: 61/937,333 →
Methods for Treating Cancer
Application: 61/948,499 →
Methods For Treating Cancer
Application: 61/951,622 →
Substituted Benzene Compounds
Application: 61/953,305 →
Substituted 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 61/953,613 →
Methods For Treating Cancer
Application: 61/992,792 →
Combination Therapy for Treating Cancer
Application: 61/992,881 →
EZH2 Inhibitors for Treating Germinal B-Cell Lymphoma
Application: 62/013,522 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/017,055 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/017,097 →
Substituted Benzene and 6,5-Fused Bicyclic Heteroaryl Compounds
Application: 62/017,221 →
DOT1L Inhibition in Patients with MN1-High Aml
Application: 62/026,583 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/033,095 →
DOT1L Inhibitors and Uses Thereof
Application: 62/035,373 →
EZH2 Inhibitors for Treating Lymphoma
Application: 62/036,265 →
Substituted Cyclohexylamine Compounds
Application: 62/048,756 →
Substituted Pyrrolidine Compounds
Application: 62/048,757 →
Isoxazole Carboxamide Compounds
Application: 62/048,759 →
Isoxazole Carboxamides as Irreversible SMYD Inhibitors
Application: 62/048,760 →
Substituted Pyrrolidine Carboxamide Compounds
Application: 62/048,763 →
Substituted Piperidine Compounds
Application: 62/048,771 →
SMYD Inhibitors
Application: 62/048,773 →
CARM1 Inhibitors and Uses Thereof
Application: 62/051,654 →
CARM1 Inhibitors and Uses Thereof
Application: 62/051,684 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/051,751 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 62/051,846 →
CARM1 Inhibitors and Uses Thereof
Application: 62/051,872 →
Salts, Co-Crystals, Amorphous Forms, and Crystalline Forms of a Co-Activator-Associated Arginine Methyltransferase 1 (CARM1) Inhibitor
Application: 62/051,878 →
Heterocycle Substituted Amino-Pyridine Compounds and Methods of Use Thereof
Application: 62/051,889 →
Combination Therapy for Treating Cancer
Application: 62/051,890 →
Salts, Co-Crystals, Amorphous Forms, and Crystalline Forms of an Arginine Methyltransferase Inhibitor
Application: 62/051,891 →
Injectable Formulations for Treating Cancer
Application: 62/051,904 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 62/051,905 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 62/051,907 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/064,357 →
Method of Treating Cancer
Application: 62/064,894 →
Method for Treating Cancer
Application: 62/064,948 →
Method for Treating Cancer
Application: 62/065,590 →
Methods for Treating Cancer
Application: 62/075,672 →
Substituted Piperidine Compounds
Application: 62/078,845 →
Method for Treating Cancer
Application: 62/080,985 →
Methods for Treating Cancer
Application: 62/088,218 →
Combination Therapy for Treating Cancer
Application: 62/088,498 →
Combination Therapy for Treating Cancer
Application: 62/110,208 →
Combination Therapy for Treating Cancer
Application: 62/112,086 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 62/115,198 →
Substituted Piperidine Compounds
Application: 62/146,790 →
Isoxazole Carboxamide Compounds
Application: 62/146,794 →
SMYD Inhibitors
Application: 62/146,799 →
Substituted Pyrrolidine Carboxamide Compounds
Application: 62/146,804 →
Substituted Pyrrolidine Compounds
Application: 62/146,808 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/148,713 →
Combination Therapy for Treating Cancer
Application: 62/149,022 →
Combination Therapy for Treating Cancer
Application: 62/150,185 →
Combination Therapy for Treating Cancer
Application: 62/165,169 →
Method for Treating Cancer
Application: 62/166,572 →
EZH2 Inhibitors for Treating Lymphoma
Application: 62/173,685 →
PRMT5 Inhibitors and Uses Thereof
Application: 62/194,459 →
Methods for Treating Cancer
Application: 62/203,283 →
Combination Therapy for Treating Cancer
Application: 62/203,285 →
Method for Treating Cancer
Application: 62/209,304 →
Method of Treating Malignant Rhabdoid Tumor of the Ovary (Mrto)/Small Cancer of the Ovary of the Hypercalcemic Type (Sccoht) with an EZH2 Inhibitor
Application: 62/233,146 →
Method of Treating Medulloblastoma with an EZH2 Inhibitor
Application: 62/238,074 →
Methods for Treating Cancer
Application: 62/250,960 →
Flow Cytometric Assay for Monitoring Epigenetic Status
Application: 62/251,322 →
Method for Treating Cancer
Application: 62/251,903 →
Pediatric Dosing for Treatment of Cancer with an EZH2 Inhibitor
Application: 62/252,190 →
Inhibitors of EZH2 and Methods of Use Thereof
Application: 62/264,169 →
Combination Therapy for Treating Cancer
Application: 62/289,050 →
Arginine Methyltransferase Inhibitors and Uses Thereof
Application: 62/292,079 →
Methods of Treating Cancer
Application: 62/292,743 →
Method of Treating Medulloblastoma with an EZH2 Inhibitor
Application: 62/299,312 →
Amine-Substituted Aryl or Heteroaryl Compounds
Application: 62/323,602 →
Use of EZH2 Inhibitors for Treating Cancer
Application: 62/344,338 →
Amine-Substituted Aryl or Heteroaryl Compounds
Application: 62/348,837 →
Flow Cytometric Assay for Monitoring Epigenetic Status
Application: 62/351,877 →
EZH2 Inhibitors for Treating Cancer
Application: 62/351,878 →
Crebbp Related Cancer Therapy
Application: 62/366,249 →
Substituted Fused Bi- or Tri- Heterocyclic Compounds as EHMT2 Inhibitors
Application: 62/402,863 →
Amine-Substituted Aryl or Heteroaryl Compounds
Application: 62/402,997 →
Inhibitors of EZH2 and Methods of Use Thereof
Application: 62/409,320 →
Inhibitors of Kat-5
Application: 62/427,732 →
Combination Therapy for Treating Cancer
Application: 62/429,612 →
Inhibitors of Kat-5
Application: 62/434,356 →
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Methods of Use Thereof
Application: 62/436,139 →
Combination Therapy for Treating Cancer
Application: 62/444,326 →
Cancer Treatment Modalities
Application: 62/453,929 →
Inhibition of SMARCA2 for Treatment of Cancer
Application: 62/464,811 →
Combination Therapy for Treating Cancer
Application: 62/466,968 →
Cancer Treatment Modalities
Application: 62/479,878 →
Methods of Using EHMT2 Inhibitors
Application: 62/480,233 →
Combination Therapy for Treating Cancer
Application: 62/480,248 →
Combination Therapies with EHMT2 Inhibitors
Application: 62/488,679 →
Substituted Fused Bi- or Tri- Heterocyclic Compounds as EHMT2 Inhibitors
Application: 62/509,620 →
Use of EZH2 Inhibitors for Treating Cancer
Application: 62/514,535 →
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Methods of Use Thereof
Application: 62/517,840 →
Inhibitors of EZH2 and Methods of Use Thereof
Application: 62/519,078 →
Combination Therapy for Treating Cancer
Application: 62/530,781 →
Use of EZH2 Inhibitors for Treating Cancer
Application: 62/530,814 →
Inhibition of SMARCA2 for Treatment of Cancer
Application: 62/542,241 →
Methods of Treating Cancer by Inhibiting SETD2
Application: 62/545,353 →
Combination Therapy for Treating Cancer
Application: 62/554,484 →
Combination Therapy for Treating Cancer
Application: 62/567,542 →
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Derivatives Thereof
Application: 62/573,442 →
Methods of Using EHMT2 Inhibitors in Preventing or Treating Blood Disorders
Application: 62/573,876 →
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors, Salts Thereof, and Methods of Synthesis Thereof
Application: 62/573,917 →
Methods of Using EHMT2 Inhibitors
Application: 62/574,095 →
Methods of Using EHMT2 Inhibitors in Immunotherapies
Application: 62/574,128 →
Combination Therapies with EHMT2 Inhibitors
Application: 62/574,147 →
Myst Family Histone Acetyltransferase Inhibitors
Application: 62/592,215 →
Halogen-Substituted Heterocyclic Compounds as EHMT2 Inhibitors, Salts Thereof, and Methods of Synthesis Thereof
Application: 62/681,804 →
Inhibitors of SMARCA2 for Treatment of Cancer
Application: 62/702,481 →
Substituted Indoles as SETD2 Inhibitors
Application: 62/718,746 →
Amine-Substituted Heterocyclic Compounds as EHMT2 Inhibitors and Derivatives Thereof
Application: 62/746,495 →
Substituted Indoles as SETD2 Inhibitors
Application: 62/773,770 →
Pyridin-2-One Compounds and Methods of Using Same
Application: 62/815,208 →
Novel Compounds and Methods of Use Thereof
Application: 62/825,507 →
Substituted Indoles as SETD2 Inhibitors
Application: 62/857,120 →
Methods of Treating WHSC1-Overexpressing Cancers by Inhibiting SETD2
Application: 62/886,880 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Feb 4, 2014
From: KUNTZ, KEVIN W.
To: EPIZYME, INC.
Reel/Frame 032137/0145 →
Assignment of Assignor's Interest Feb 4, 2014
From: KEILHACK, HEIKE; KNUTSON, SARAH KATHLEEN; KUNTZ, KEVIN WAYNE
To: EPIZYME, INC.
Reel/Frame 032137/0066 →
Assignment of Assignor's Interest Feb 4, 2014
From: POLLOCK, ROY M.; DAIGLE, SCOTT R.
To: EPIZYME, INC.
Reel/Frame 032137/0549 →
Assignment of Assignor's Interest Feb 4, 2014
From: HUANG, KUAN-CHUN; CHOI, HYEONG WOOK; SANDERS, KRISTEN; MATHIEU, STEVEN
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 032137/0348 →
Assignment of Assignor's Interest Apr 25, 2014
From: DUNCAN, KENNETH W.; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN; JIN, LEI
To: EPIZYME, INC.
Reel/Frame 032759/0493 →
Assignment of Assignor's Interest May 21, 2014
From: KUNTZ, KEVIN WAYNE; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; CHESWORTH, RICHARD
To: EPIZYME, INC.
Reel/Frame 032942/0918 →
Assignment of Assignor's Interest May 21, 2014
From: MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; CHESWORTH, RICHARD; MORADEI, OSCAR MIGUEL
To: EPIZYME, INC.
Reel/Frame 032943/0001 →
Assignment of Assignor's Interest May 21, 2014
From: DUNCAN, KENNETH W.; CHESWORTH, RICHARD; MUNCHHOF, MICHAEL JOHN; JIN, LEI
To: EPIZYME, INC.
Reel/Frame 032943/0170 →
Assignment of Assignor's Interest May 21, 2014
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; KUNTZ, KEVIN WAYNE
To: EPIZYME, INC.
Reel/Frame 032943/0118 →
Assignment of Assignor's Interest May 29, 2014
From: DUNCAN, KENNETH W.; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN; MUNCHHOF, MICHAEL JOHN
To: EPIZYME, INC.
Reel/Frame 032990/0170 →
Assignment of Assignor's Interest May 29, 2014
From: DUNCAN, KENNETH W.; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN; MUNCHHOF, MICHAEL JOHN
To: EPIZYME, INC.
Reel/Frame 032990/0093 →
Assignment of Assignor's Interest Jun 3, 2014
From: DUNCAN, KENNETH W.; CHESWORTH, RICHARD; MUNCHHOF, MICHAEL JOHN
To: EPIZYME, INC.
Reel/Frame 033018/0885 →
Assignment of Assignor's Interest Jun 3, 2014
From: DUNCAN, KENNETH W.; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN; MUNCHHOF, MICHAEL JOHN
To: EPIZYME, INC.
Reel/Frame 033019/0287 →
Assignment of Assignor's Interest Jun 3, 2014
From: MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN
To: EPIZYME, INC.
Reel/Frame 033019/0219 →
Assignment of Assignor's Interest Jun 5, 2014
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON
To: EPIZYME, INC.
Reel/Frame 033040/0462 →
Assignment of Assignor's Interest Jun 5, 2014
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; MORADEI, OSCAR MIGUEL
To: EPIZYME, INC.
Reel/Frame 033040/0312 →
Assignment of Assignor's Interest Jun 5, 2014
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; BORIACK-SJODIN, PAULA ANN
To: EPIZYME, INC.
Reel/Frame 033040/0091 →
Assignment of Assignor's Interest Jun 5, 2014
From: MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; CHESWORTH, RICHARD; BORIACK-SJODIN, PAULA ANN
To: EPIZYME, INC.
Reel/Frame 033040/0530 →
Assignment of Assignor's Interest Jun 5, 2014
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON
To: EPIZYME, INC.
Reel/Frame 033040/0409 →
Assignment of Assignor's Interest Sep 18, 2014
From: CAMPBELL, JOHN EMMERSON; KUNTZ, KEVIN WAYNE
To: EPIZYME, INC.
Reel/Frame 033768/0831 →
Assignment of Assignor's Interest Oct 9, 2014
From: CAMPBELL, JOHN EMMERSON; KUNTZ, KEVIN WAYNE
To: EPIZYME, INC.
Reel/Frame 033924/0337 →
Assignment of Assignor's Interest Oct 23, 2014
From: CHESWORTH, RICHARD; MORADEI, OSCAR MIGUEL; SHAPIRO, GIDEON; DUNCAN, KENNETH W.
To: EPIZYME, INC.
Reel/Frame 034013/0536 →
Assignment of Assignor's Interest Oct 23, 2014
From: CHESWORTH, RICHARD; MORADEI, OSCAR MIGUEL; SHAPIRO, GIDEON; JIN, LEI
To: EPIZYME, INC.
Reel/Frame 034013/0488 →
Assignment of Assignor's Interest Jan 14, 2015
From: CHESWORTH, RICHARD; MITCHELL, LORNA HELEN; SHAPIRO, GIDEON; SWINGER, KERREN K.
To: EPIZYME, INC.
Reel/Frame 034702/0962 →
Assignment of Assignor's Interest Mar 19, 2015
From: POLLOCK, ROY M.; DAIGLE, SCOTT R.; HEDRICK, ERIC; WATERS, NIGEL
To: EPIZYME, INC.
Reel/Frame 035208/0628 →